About Curasight
Curasight is a company based in Copenhagen (Denmark) founded in 2013 by Carsten Haagen Nielsen and Jacob Madsen. It operates as a HealthTech. Curasight has raised $11.54 million across 4 funding rounds from investors including PreSeed Ventures. The company has 9 employees as of November 30, 2024. Curasight offers products and services including uTREAT® and uTRACE®. Curasight operates in a competitive market with competitors including OncoStem, PreludeDx, Miltel, POC Medical Systems and Inbiomotion, among others.
- Headquarter Copenhagen, Denmark
- Employees 9 as on 30 Nov, 2024
- Founders Carsten Haagen Nielsen, Jacob Madsen
- Stage Minicorn
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Curasight A/S
-
Annual Revenue
-
Net Profit
$-2.6 M (USD)-65as on Dec 31, 2022
-
EBITDA
$-2.37 M (USD)-55as on Dec 31, 2022
-
Total Equity Funding
$11.54 M (USD)
in 4 rounds
-
Latest Funding Round
$7.4 M (USD), Series A
Sep 22, 2020
- Investors
-
Employee Count
9
as on Nov 30, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Curasight
Curasight offers a comprehensive portfolio of products and services, including uTREAT® and uTRACE®. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Targeted radiation therapy is used for cancer treatment.
uPAR-PET imaging is used for cancer diagnosis accuracy.
Unlock access to complete
Funding Insights of Curasight
Curasight has successfully raised a total of $11.54M across 4 strategic funding rounds. The most recent funding activity was a Series A round of $7.4 million completed in September 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 4
- Last Round Series A — $7.4M
-
First Round
First Round
(19 May 2014)
- Investors Count 1
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep, 2020 | Amount | Series A - Curasight | Valuation |
investors |
|
| Jun, 2017 | Amount | Seed - Curasight | Valuation |
investors |
|
| Jun, 2015 | Amount | Seed - Curasight | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Curasight
Curasight has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include PreSeed Ventures. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Curasight
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Curasight
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Curasight Comparisons
Competitors of Curasight
Curasight operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as OncoStem, PreludeDx, Miltel, POC Medical Systems and Inbiomotion, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Prognostic tests for cancer detection and recurrence risk are developed.
|
|
| domain | founded_year | HQ Location |
Risk assessment tests for early-stage breast cancer are provided.
|
|
| domain | founded_year | HQ Location |
Telomere tests for aging detection and cellular senescence are provided.
|
|
| domain | founded_year | HQ Location |
Develops rapid tools for breast cancer detection and disease screening worldwide.
|
|
| domain | founded_year | HQ Location |
Biomarkers for predicting bone metastasis in cancer patients are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Curasight
Frequently Asked Questions about Curasight
When was Curasight founded?
Curasight was founded in 2013 and raised its 1st funding round 1 year after it was founded.
Where is Curasight located?
Curasight is headquartered in Copenhagen, Denmark.
Who is the current CEO of Curasight?
Ulrich Alexander Krasilnikoff is the current CEO of Curasight.
Is Curasight a funded company?
Curasight is a funded company, having raised a total of $11.54M across 4 funding rounds to date. The company's 1st funding round was a Seed of $1.33M, raised on May 19, 2014.
How many employees does Curasight have?
As of Nov 30, 2024, the latest employee count at Curasight is 9.
What does Curasight do?
Curasight, a Danish biotech company, is dedicated to improving cancer care through innovative technologies. The company specializes in uPAR Theranostics, combining targeted uTREAT radiation therapy with precise uTRACE diagnostics to minimize harm to healthy tissue. Focus areas include brain and prostate cancer, with several phase II clinical trials completed or ongoing. Solutions are built on deep research into the uPAR system, aiming to enhance diagnosis and treatment outcomes in the healthcare sector.
Who are the top competitors of Curasight?
Curasight's top competitors include PreludeDx, OncoStem and Gamma Medica.
What products or services does Curasight offer?
Curasight offers uTREAT® and uTRACE®.
Who are Curasight's investors?
Curasight has 1 investor. Key investors include PreSeed Ventures.
What is Curasight's valuation?
The valuation of Curasight is $38.8M as of Sep 2020.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.